ZyVersa Therapeutics, Inc. (ZVSA)
Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014Q1-CY2014Q4-CY2013
Balance Sheet Date2025-Sep-302025-Jun-302025-Mar-312024-Dec-312024-Sep-302024-Jun-302024-Mar-312023-Dec-31
Fiscal PeriodQ3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024Q3-FY2024Q2-FY2024Q1-FY2024Q4-FY2023
Operating Cash Flow(1,406,912$)(1,521,728$)(1,772,052$)(1,254,868$)(614,141$)(1,914,090$)(3,776,598$)(2,787,352$)(936,395$)(407,620$)(4,589,452$)
Investing Cash Flow
Purchases of Property and Equipment
Financing Cash Flow1,862,804$(17,718$)1,852,660$2,662,871$617,576$0$2,672,500$4,346,305$2,286,424$(641,761$)(34,674$)
End Cash Position527,978$72,086$1,611,532$1,530,924$122,921$119,486$2,033,576$3,137,674$1,578,721$228,693$1,278,073$5,902,199$
Exchange Rate Effect
Dividends Paid
Unlevered Free Cash Flow(1,406,912$)(1,521,728$)(1,772,052$)(1,254,868$)(614,141$)(1,914,090$)(3,776,598$)(2,787,352$)(936,395$)(407,620$)(4,589,452$)